/PRNewswire/ UCB, a global biopharmaceutical company, today announced new data on its investigational IL-17A and IL-17F inhibitor, bimekizumab, and its TNF.
AbbVie Presents Integrated Efficacy and Safety Data From Two Phase 3 Trials on Risankizumab in Psoriatic Arthritis at ACR Convergence 2021 investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.
LONDON (dpa-AFX) - AbbVie (ABBV) said that it will present integrated data from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2, which evaluated the efficacy and safety of risankizumab or
/PRNewswire/ AbbVie (NYSE: ABBV) today announced the presentation of integrated data from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2, evaluating.
/PRNewswire/ AbbVie (NYSE: ABBV) today announced the presentation of integrated data from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2, evaluating.